Latest Archer Materials (ASX:AXE) News

Archer Materials has achieved critical milestones in its carbon-based quantum technology, including wafer-scale synthesis and reproducible device performance, setting the stage for operational qubits by mid-2026.

Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.

Archer Materials has partnered with Belgium’s IMEC to develop a scalable, cost-effective potassium ion biosensor using silicon semiconductor technology, aiming to accelerate commercial production by late 2025.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

Archer Materials has successfully demonstrated its tunnel magnetoresistance (TMR) sensors operating at cryogenic temperatures, marking a key advance for quantum computing and advanced sensing applications.

Archer Materials has achieved a significant milestone by integrating its graphene-based sensors with silicon readout circuitry, paving the way for a compact, at-home potassium testing device aimed at chronic kidney disease management.

Archer Materials has teamed up with UK-based Paragraf to fast-track development of its Biochip sensor for at-home chronic kidney disease testing, aiming to enhance accuracy and product readiness over six months.

Archer Materials has successfully detected spin states in its carbon-based quantum material using a novel resonator design, marking a pivotal step toward functional qubit development for quantum computing.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.